We know scientists have busy schedules. 🤷 That's why we put together #ProstateCell News, an online publication and bi-weekly email newsletter covering the latest research into breast cancer and mammary cells. 📰 Subscribe here: bit.ly/4kkWMEu

Findings in a @NatureComms study identify nuclear receptor coactivator 6 as a potent tumor suppressor and a clinically relevant biomarker to identify prostate cancer patients most likely to benefit from EGFR-targeted therapy. Read the paper here📝 : go.nature.com/4rAchNd #ProstateCancer #EGFR

A new study reports that SSC185 reduced the MTT signal of PC-3 prostate cancer cells in a concentration- and time-dependent manner, with nutrient deprivation markedly enhancing its activity, indicating that the cellular nutritional context influences the response to the compound. Read the full paper: bit.ly/46TRHOa Led by first author Gisele Santos de Araújo and corresponding author Ana Jérsia Araujo at @UFDPar. #ProstateCancer #Oncology #DrugDiscovery

Restoring DPP4 expression via capsaicin suppresses prostate tumorigenesis in castration-resistant prostate cancer (CRPC) models, suggesting DPP4 could be a new target for CRPC. Read the study: bit.ly/3VAf4K9 Led by first author José María Mora-Rodríguez and corresponding author Inés Díaz-Laviada at the University of Alcalá and IDISCAM. #ProstateCancer #Oncology #DrugDiscovery

Researchers from Shaanxi Normal University identified BIRC6-AS1/BIRC6 as a significant contributor to abiraterone resistance in prostate cancer. They found depletion enhanced the sensitivity of prostate cancer cells to abiraterone in both in vitro and in vivo settings. Read the full paper: go.nature.com/4yUsDSX #ProstateCancer #CancerResearch #Oncology

A new study shows that PHD2-regulated degradation of HIFα contributes to PGC1α/ERRα-mediated prostate cancer suppression, providing a new component to the tumor-suppressive activity of the PGC1α/ERRα complex. Read the @Nature paper here: go.nature.com/4AqE9XS Led by first author Maider Fagoaga-Eugui and corresponding authors Arkaitz Carracedo and Edurne Berra at @upvehu, CIBERONC, and participating instiutions. #ProstateCancer #Oncology #CancerResearch

🧬 Exciting @Nature article delineates the etiologies and mutational processes that drive the genomic and clinical heterogeneity of #ProstateCancer. 👓 Read how they investigated the #genomes of 959 donors: go.nature.com/4he7snZ

🧪 Researchers at Soochow University compared magnetic nanomaterials to find the best #ExtracellularVesicle capture performance, which can enable early diagnosis and precision therapy in #ProstateCancer using urine samples. 👓 Read the article here: bit.ly/4j0qJLV

🦠 New research in @NatureCancer reveals that the gut-to-tumor translocation of N. glabratus contributes to endocrine resistance in #ProstateCancer. Read the #OpenAccess article here: go.nature.com/4xPyOaO

Read this interesting study from @ucl investigating how magnetic hyperthermia therapy induces cell death in #ProstateCancer and #melanoma cells. 👇 rsc.li/4xdwg5q

🦠Read about how the gut microbiota is linked to benign prostatic diseases like #ChronicPelvicPainSyndrome and #BenignProstaticHyperplasia in this review👇 bit.ly/4zXQbYq

Researchers including Alexandra Nukovic show that an O2-generating platform, Click O2-CryogelVAX, targeting the tumor-associated antigen prostatic acid phosphatase, enhances adaptive immune responses, and provides therapeutic benefits in a #ProstateCancer model. 🔗 bit.ly/46GmJsF

Researchers with first author Joyeeta Chatterjee develop a CDK2 inhibitor-resistant #CastrateResistantProstateCancer (CRPC) model and perform a rational compound screen to assess which of the currently used anti-CRPC treatments could augment CDK2 therapy-response. 💊 bit.ly/4ic75MF #OpenAccess

Dr. Neil Lin's @UCLAengineering team has been awarded a $2.1 million grant by the US Department of Defense to support a new research approach merging genetic testing, functional drug-sensitivity testing and advanced computer modeling into a single system for guiding #ProstateCancer therapy. Check out the press release: bit.ly/4gHhsFP

Using a transgenic mouse model, scientists with Dr. Michela Perego show that early stages of neuroendocrine prostate cancer are associated with increased intraprostatic recruitment of Ly6G+ polymorphonuclear neutrophils and reduced infiltration of CD8+ T cells. go.nature.com/4qTDWs6

Investigators identified the chromatin remodeler HELLS as a critical oncogenic driver in prostate cancer and elucidated a previously unrecognized post-translational cascade that governs its protein stability. bit.ly/4x4tEqd

Dr. Joan Montero's lab at the University of Barcelona found that BCL-xL is the major pro-survival protein in #ProstateCancer cell lines after docetaxel treatment. As well, they identified which proteins are downregulated in cells with BCL-xL mediated resistance. 📝 go.nature.com/4hV9g7g

The dysregulation of mRNA modifications has emerged as a pivotal mechanism in tumor biology. This study revealed that NAT10 facilitates mRNA modifications in the progression of #ProstateCancer through ac4C modification of MARK2. 🧪 See the abstract: go.nature.com/4qG7PvH

Scientists' findings identified #Olaparib-induced CD73 upregulation as an adaptive resistance mechanism and support Olaparib plus CD73 blockade as a promising therapeutic strategy for advanced #ProstateCancer, irrespective of homologous recombination repair status. 💡 🔗 bit.ly/4xC5SmV

Researchers revealed a promising therapeutic strategy for castration-resistant #ProstateCancer and demonstrate how metabolic plasticity can be fatally impaired by cotargeting upstream oncogenic nodes that converge on this important process. 🔬 Learn more: bit.ly/4xoh32g #OpenAccess